Tumor-associated peptides that bind to MHC-molecules
AssigneeImmatics Biotechnologies GmbH
InventorsToni Weinschenk, Claudia Lemmel, Hans-Georg Rammensee, Stefan Stevanovic
Life of this patent
Estimating the term…
Abstract
The invention relates to a tumor-associated peptide with an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 577 from the attached sequence protocol, the peptide being capable of binding to a molecule of the human major histocompatibilityg complex (MHC) class I. The invention further relates to the use of the peptides for preparation of a drug and for the treatment of tumor diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described comprising at least one of the peptides.
Claims19
An isolated peptide consisting of SEQ ID NO:
- 448.
An isolated peptide consisting of SEQ ID NO:
- 448, with the proviso that one amino acid of SEQ ID NO:
- 448 is replaced by another amino acid with similar chemical properties, the peptide being capable of binding to a molecule of the human major histocompatibility complex (MHC) class I.
An isolated peptide consisting of SEQ ID NO:
- 448 and one additional amino acids at the N or/and C-terminus thereof, the peptide being capable of binding to a molecule of the human major histocompatibility complex (MHC) class I.
Dependencies are inferred from the claim text.